Prosight Management, LP Cue Biopharma, Inc. Transaction History

Prosight Management, LP

$372 Million
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$2.41 - $3.74 $1.66 Million - $2.58 Million	-688,655 Reduced 37.42%	1,151,855 $4.11 Million
Q4 2022 Feb 14, 2023	BUY	$2.39 - $3.95 $704,899 - $1.17 Million	294,937 Added 19.08%	1,840,510 $5.25 Million
Q3 2022 Nov 14, 2022	SELL	$2.23 - $3.37 $245,085 - $370,376	-109,904 Reduced 6.64%	1,545,573 $3.45 Million
Q2 2022 Aug 12, 2022	BUY	$2.49 - $5.92 $361,535 - $859,554	145,195 Added 9.61%	1,655,477 $4.12 Million
Q1 2022 May 16, 2022	BUY	$4.41 - $12.28 $3 Million - $8.37 Million	681,240 Added 82.17%	1,510,282 $7.37 Million
Q4 2021 Feb 14, 2022	BUY	$10.86 - $17.85 $1.89 Million - $3.1 Million	173,857 Added 26.54%	829,042 $9.38 Million
Q3 2021 Nov 12, 2021	BUY	$10.06 - $15.3 $249,699 - $379,761	24,821 Added 3.94%	655,185 $9.55 Million
Q2 2021 Aug 13, 2021	BUY	$10.9 - $14.53 $802,098 - $1.07 Million	73,587 Added 13.22%	630,364 $7.34 Million
Q1 2021 May 14, 2021	SELL	$11.2 - $16.09 $3.92 Million - $5.63 Million	-349,792 Reduced 38.58%	556,777 $6.79 Million
Q4 2020 Feb 12, 2021	BUY	$11.12 - $16.4 $2.19 Million - $3.22 Million	196,633 Added 27.7%	906,569 $11.3 Million
Q3 2020 Nov 13, 2020	BUY	$15.05 - $23.54 $6.01 Million - $9.41 Million	399,642 Added 128.79%	709,936 $10.7 Million
Q2 2020 Aug 14, 2020	SELL	$12.7 - $30.73 $3.07 Million - $7.43 Million	-241,766 Reduced 43.79%	310,294 $7.61 Million
Q1 2020 May 15, 2020	BUY	$9.85 - $22.27 $4.08 Million - $9.23 Million	414,432 Added 301.12%	552,060 $7.83 Million
Q4 2019 Feb 14, 2020	BUY	$7.06 - $17.47 $971,653 - $2.4 Million	137,628 New	137,628 $2.19 Million

Others Institutions Holding CUE

# of Institutions

Shares Held

14.1M

Call Options Held

14.4K

Put Options Held

2.6K

View Full List

About Cue Biopharma, Inc.

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $38.2M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

More about CUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Prosight Management, LP with notifications on news.

Account